Who
Joseph K. Schachle
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Opus Genetics; EVP, Pulmonary Business, Inspire Pharmaceuticals.
In numbers
- Trades disclosed
- 66
- Buys
- 1
- Sells
- 3
- Bought
- $4,100
- Sold
- $115K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 19 Jan 2006
- Last trade
- 23 Jul 2026
- Last filed
- 27 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $14K4,644 at $2.94 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $14K4,644 at $2.94 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $25K4,697 at $5.22 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $25K4,697 at $5.22 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $20K3,719 at $5.25 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $20K3,719 at $5.25 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Bought | $4,1002,000 at $2.05 | filing |
| 27 Nov 2023filed 27 Nov 2023 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —26,000 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —26,000 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —13,250 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —13,250 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 13 May 2011filed 16 May 2011 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
News
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessIRD · manilatimes.net · 21 Oct 2026Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Joseph K. Schachle; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.